Skip to main content
SMFM 2026 Pregnancy Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Additional registration fee required
Additional registration fee required
Faculty have requested this content not be shared outside of the session
Faculty have requested this content not be shared outside of the session
CME Credit Offered
CME Credit Offered
Abstract Award
Abstract Award
Recording available 2/16-5/2
Recording available 2/16-5/2
AIUM Credit
AIUM Credit
Foundation Awardee
Foundation Awardee
Poster Icons
Abstract Award
Abstract Award
Foundation Awardee
Foundation Awardee

Poster Session 1

Category: Health Equity/Community Health

Poster Session 1

(144) Prenatal vaccination rates post-pandemic in pregnant persons with and without medical co-morbidities

Wednesday, February 11, 2026
10:30 AM - 12:00 PM  
Objective:
To evaluate how the coronavirus disease 2019 (COVID-19) pandemic affected influenza, tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (TDaP), and COVID-19 vaccination rates in a pregnant population with medical co-morbidities. 

Study Design:
Retrospective cohort study utilizing the EPIC COSMOS database to evaluate influenza, TDaP, and COVID-19 vaccination rates in pregnant patients who had a hypertensive disorder of pregnancy, asthma, or pregestational/gestational diabetes mellitus (DM) from 2016 to 2024. Multivariable logistic regression modeling was conducted to evaluate the effect of time and factors of interest on vaccine rates.

Results:
There were 23,118,213 patients eligible for vaccination during pregnancy, 5,852,492 of whom had hypertensive disorders of pregnancy, asthma, or pregestational/gestational DM. The high-risk group had significantly higher vaccination rates across all three vaccines compared to the general population (p < 0.001). There was an increase in influenza and TDaP vaccination rates until 2020, after which there was a decrease in vaccination rates almost to pre-pandemic levels (p < 0.001). Peak COVID-19 vaccination rates in the high-risk group occurred in 2021 at 16.5% followed by a decline down to 0.05% by 2024. These were significantly higher than rates in the general pregnant population of 14.4% and 0.04%, respectively (p < 0.001). TDaP vaccination rates were significantly higher than influenza vaccination rates at peak uptake, 52.2% vs 29% respectively (p < 0.001).  

Conclusion:
Pregnant patients with medical co-morbidities had higher vaccination rates than low-risk pregnancies. Influenza and TDaP vaccination rates increased until the COVID-19 pandemic began in 2020 and then declined. COVID-19 vaccination rates peaked in 2021 followed by a significant decline. This decline in all three vaccination rates highlights the importance of clear, evidence-based guidance, particularly for pregnant patients at high risk for disease.